ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has been announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.

U.K.-based Glaxo said its HIV pill dolutegravir plus Johnson & Johnson’s rilpivirine suppressed the virus as well as traditional three- or four-drug combinations in two identical, yearlong trials, each involving around 500 patients.

Dominique Limet, who leads ViiV Healthcare, said the company would submit the two-drug combination to regulators next year. Both medicines are already sold as components in combinations of three drugs or more.

Read further on Wall Street Journal 12/21/2016